{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:24:15Z","timestamp":1785781455895,"version":"3.56.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministry of Education Youth and Sports of the Czech Republic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Czech Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.biopha.2026.119045","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T01:35:36Z","timestamp":1769909736000},"page":"119045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Empagliflozin in combination with trandolapril but not with triple therapy improves glucose and lipid metabolism in non-diabetic hypertensive model"],"prefix":"10.1016","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2487-7283","authenticated-orcid":false,"given":"Silvie","family":"Hojn\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Mal\u00ednsk\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"H\u00fcttl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4331-7636","authenticated-orcid":false,"given":"Irena","family":"Markov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zde\u0148ka","family":"Va\u0148ourkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisa","family":"Mikl\u00e1nkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6306-5134","authenticated-orcid":false,"given":"Jaroslav","family":"Hrdli\u010dka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franti\u0161ek","family":"Papou\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Neck\u00e1\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Behuliak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Rauchov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7266-9833","authenticated-orcid":false,"given":"Mahak","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Kadlecov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Zicha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Van\u011b\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.biopha.2026.119045_bib1","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.biopha.2026.119045_bib2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119045_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12933-020-0994-y","article-title":"Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction","volume":"19","author":"Connelly","year":"2020","journal-title":"Cardiovasc Diabetol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119045_bib4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/CIRCULATIONAHA.119.044359","article-title":"Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: results from the CREDENCE trial","volume":"141","author":"Cannon","year":"2020","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.biopha.2026.119045_bib5","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/ndt\/gfaa234","article-title":"The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics","volume":"35","author":"Wheeler","year":"2020","journal-title":"Nephrol. Dial. Transpl."},{"issue":"1","key":"10.1016\/j.biopha.2026.119045_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S2213-8587(21)00292-8","article-title":"Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial","volume":"10","author":"Verma","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119045_bib7","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2666-7568(23)00032-6","article-title":"Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial","volume":"4","author":"Pratley","year":"2023","journal-title":"Lancet Healthy Longev."},{"issue":"4","key":"10.1016\/j.biopha.2026.119045_bib8","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ejhf.3240","article-title":"Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: insights from the SCORED randomized trial","volume":"26","author":"Aggarwal","year":"2024","journal-title":"Eur. J. Heart Fail"},{"issue":"8 Pt 1","key":"10.1016\/j.biopha.2026.119045_bib9","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jchf.2023.05.026","article-title":"Effect of sotagliflozin on early mortality and heart failure-related events: a post hoc analysis of SOLOIST-WHF","volume":"11","author":"Pitt","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.biopha.2026.119045_bib10","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00177.2023","article-title":"Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench","volume":"325","author":"Chen","year":"2023","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119045_bib11","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00528.2022","article-title":"Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system","volume":"324","author":"Chen","year":"2023","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.biopha.2026.119045_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112606","article-title":"Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5\/6 nephrectomised rats on high salt diet","volume":"146","author":"Zeng","year":"2022","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2026.119045_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116520","article-title":"Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet","volume":"174","author":"Hojn\u00e1","year":"2024","journal-title":"Biomed. Pharm."},{"issue":"21","key":"10.1016\/j.biopha.2026.119045_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111513","article-title":"In a prediabetic model, empagliflozin improves hepatic lipid metabolism independently of obesity and before onset of hyperglycemia","volume":"22","author":"H\u00fcttl","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119045_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112246","article-title":"Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension","volume":"144","author":"Hojn\u00e1","year":"2021","journal-title":"Biomed. Pharm."},{"issue":"9","key":"10.1016\/j.biopha.2026.119045_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10092066","article-title":"Beneficial effects of empagliflozin are mediated by reduced renal inflammation and oxidative stress in spontaneously hypertensive rats expressing human C-reactive protein","volume":"10","author":"Mal\u00ednsk\u00e1","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.biopha.2026.119045_bib17","article-title":"Gliflozins in the treatment of non-diabetic experimental cardiovascular diseases","author":"Van\u011b\u010dkov\u00e1","year":"2024","journal-title":"Physiol. Res 73"},{"issue":"6","key":"10.1016\/j.biopha.2026.119045_bib18","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/ki.1996.265","article-title":"The hyperfiltration theory: a paradigm shift in nephrology","volume":"49","author":"Brenner","year":"1996","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.biopha.2026.119045_bib19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/HJH.0000000000003633","article-title":"Combining renin-angiotensin system blockade and sodium-glucose cotransporter-2 inhibition in experimental diabetes results in synergistic beneficial effects","volume":"42","author":"Cruz-L\u00f3pez","year":"2024","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2026.119045_bib20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.biopha.2018.03.176","article-title":"Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy","volume":"103","author":"Abdel-Wahab","year":"2018","journal-title":"Biomed. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2026.119045_bib21","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1007\/s11357-022-00610-7","article-title":"Renoprotective effects of empagliflozin in type 1 and type 2 models of diabetic nephropathy superimposed with hypertension","volume":"44","author":"Williams","year":"2022","journal-title":"Geroscience"},{"issue":"5","key":"10.1016\/j.biopha.2026.119045_bib22","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/HJH.0000000000003099","article-title":"Cardiorenal protective effects of sodium-glucose cotransporter 2 inhibition in combination with angiotensin II type 1 receptor blockade in salt-sensitive Dahl rats","volume":"40","author":"Ito","year":"2022","journal-title":"J. Hypertens."},{"issue":"12","key":"10.1016\/j.biopha.2026.119045_bib23","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1097\/01.hjh.0000251909.00923.22","article-title":"AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage in Cyp1a1-Ren-2 transgenic rats with inducible hypertension","volume":"24","author":"Vanourkov\u00e1","year":"2006","journal-title":"J. Hypertens."},{"issue":"1","key":"10.1016\/j.biopha.2026.119045_bib24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"issue":"7-8","key":"10.1016\/j.biopha.2026.119045_bib25","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.nut.2015.03.011","article-title":"Conjugated linoleic acid reduces visceral and ectopic lipid accumulation and insulin resistance in chronic severe hypertriacylglycerolemia","volume":"31","author":"Malinska","year":"2015","journal-title":"Nutrition"},{"issue":"4","key":"10.1016\/j.biopha.2026.119045_bib26","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/apha.12092","article-title":"Chronic antioxidant therapy lowers blood pressure in adult but not in young Dahl salt hypertensive rats: the role of sympathetic nervous system","volume":"208","author":"Van\u011b\u010dkov\u00e1","year":"2013","journal-title":"Acta Physiol. (Oxf. )"},{"issue":"2","key":"10.1016\/j.biopha.2026.119045_bib27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1042\/cs0890177","article-title":"Contribution of vascular nitric oxide to basal blood pressure in conscious spontaneously hypertensive rats and normotensive Wistar Kyoto rats","volume":"89","author":"Minami","year":"1995","journal-title":"Clin. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2026.119045_bib28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/hr.2012.29","article-title":"The effects of repeated delivery of angiotensin II AT(1) receptor antisense on distinct vasoactive systems in Ren-2 transgenic rats: young vs. adult animals","volume":"35","author":"Van\u011b\u010dkov\u00e1","year":"2012","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.biopha.2026.119045_bib29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fphar.2019.00159","article-title":"Epoxyeicosatrienoic acid-based therapy attenuates the progression of postischemic heart failure in normotensive sprague-dawley but not in hypertensive Ren-2 transgenic rats","volume":"10","author":"Hrdli\u010dka","year":"2019","journal-title":"Front Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2026.119045_bib30","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41440-018-0198-y","article-title":"Which sympathoadrenal abnormalities of adult spontaneously hypertensive rats can be traced to a prehypertensive stage?","volume":"42","author":"Vav\u0159\u00ednov\u00e1","year":"2019","journal-title":"Hypertens. Res."},{"issue":"10","key":"10.1016\/j.biopha.2026.119045_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10102509","article-title":"Empagliflozin is not renoprotective in non-diabetic rat models of chronic kidney disease","volume":"10","author":"Hojn\u00e1","year":"2022","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.biopha.2026.119045_bib32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000505144","article-title":"Renal anti-fibrotic effect of sodium glucose cotransporter 2 inhibition in angiotensin II-dependent hypertension","volume":"51","author":"Castoldi","year":"2020","journal-title":"Am. J. Nephrol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119045_bib33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.33594\/000000003","article-title":"Effects of the SGLT-2 inhibitor canagliflozin on adenine-induced chronic kidney disease in rats","volume":"52","author":"Ali","year":"2019","journal-title":"Cell Physiol. Biochem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119045_bib34","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00119.2025","article-title":"Gliflozins in hypertension: basic mechanisms and clinical insights","volume":"329","author":"Rieg","year":"2025","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119045_bib35","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1007\/s11357-024-01250-9","article-title":"Empagliflozin rescues lifespan and liver senescence in naturally aged mice","volume":"46","author":"Long","year":"2024","journal-title":"Geroscience"},{"key":"10.1016\/j.biopha.2026.119045_bib36","article-title":"Widespread discordance between mRNA expression, protein abundance and de novo lipogenesis activity in hepatocytes during the fed-starvation transition","author":"Landgraf","year":"2025","journal-title":"bioRxiv"},{"issue":"6","key":"10.1016\/j.biopha.2026.119045_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection","volume":"23","author":"Androutsakos","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119045_bib38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.biopha.2026.119045_bib39","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12882-019-1490-z","article-title":"Role of sodium\/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage","volume":"20","author":"Reyes-Pardo","year":"2019","journal-title":"BMC Nephrol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119045_bib40","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00445.2017","article-title":"Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study","volume":"314","author":"Rajasekeran","year":"2018","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.biopha.2026.119045_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106659","article-title":"Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome","volume":"188","author":"Urbanek","year":"2023","journal-title":"Pharm. Res"},{"key":"10.1016\/j.biopha.2026.119045_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113947","article-title":"Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5\/6-nephrectomy","volume":"156","author":"Lu","year":"2022","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2026.119045_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118497","article-title":"Empagliflozin reduces left ventricular mass increase and improves cardiomyocyte hypertrophy after 5\/6 nephrectomy","volume":"191","author":"Chen","year":"2025","journal-title":"Biomed. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2026.119045_bib44","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0895-7061(03)00003-7","article-title":"Trandolapril and endothelin antagonist LU-135252 in the treatment of the fructose-induced hypertensive, hyperinsulinemic, hypertriglyceridemic rat","volume":"16","author":"Ezra-Nimni","year":"2003","journal-title":"Am. J. Hypertens."},{"issue":"2","key":"10.1016\/j.biopha.2026.119045_bib45","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/08037050510008913","article-title":"Endothelin A antagonist LU-135252 and trandolapril in the treatment of the Cohen-Rosenthal diabetic hypertensive rat","volume":"14","author":"Hofman","year":"2005","journal-title":"Blood Press"},{"issue":"6","key":"10.1016\/j.biopha.2026.119045_bib46","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/FJC.0b013e318177090d","article-title":"Angiotensin-converting enzyme inhibitors, inhibition of brain and peripheral angiotensin-converting enzymes, and left ventricular dysfunction in rats after myocardial infarction","volume":"51","author":"Ahmad","year":"2008","journal-title":"J. Cardiovasc Pharm."},{"issue":"2 Pt 1","key":"10.1016\/j.biopha.2026.119045_bib47","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.amjhyper.2004.09.004","article-title":"Inhibition of brain angiotensin-converting enzyme by peripheral administration of trandolapril versus lisinopril in Wistar rats","volume":"18","author":"Tan","year":"2005","journal-title":"Am. J. Hypertens."},{"issue":"1","key":"10.1016\/j.biopha.2026.119045_bib48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11906-025-01342-7","article-title":"Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists","volume":"27","author":"Siddiqi","year":"2025","journal-title":"Curr. Hypertens. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2026.119045_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9081053","article-title":"Effects of Epoxyeicosatrienoic acid-enhancing therapy on the course of congestive heart failure in angiotensin II-dependent rat hypertension: from mRNA analysis towards functional in vivo evaluation","volume":"9","author":"Kala","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.biopha.2026.119045_bib50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/HJH.0000000000003307","article-title":"Endothelin type A receptor blockade attenuates aorto-caval fistula-induced heart failure in rats with angiotensin II-dependent hypertension","volume":"41","author":"Kala","year":"2023","journal-title":"J. Hypertens."},{"issue":"11","key":"10.1016\/j.biopha.2026.119045_bib51","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/CS20110622","article-title":"Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension","volume":"122","author":"Neck\u00e1\u0159","year":"2012","journal-title":"Clin. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2026.119045_bib52","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1038\/s41440-024-01793-6","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on blood pressure in patients with type 2 diabetes and cardiovascular diseases","volume":"47","author":"Asanuma","year":"2024","journal-title":"Hypertens. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119045_bib53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.33549\/physiolres.932717","article-title":"Nifedipine-sensitive blood pressure component in hypertensive models characterized by high activity of either sympathetic nervous system or renin-angiotensin system","volume":"63","author":"Zicha","year":"2014","journal-title":"Physiol. Res."},{"key":"10.1016\/j.biopha.2026.119045_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116796","article-title":"Chronic inhibition of angiotensin converting enzyme lowers blood pressure in spontaneously hypertensive rats by attenuation of sympathetic tone: the role of enhanced baroreflex sensitivity","volume":"176","author":"Behuliak","year":"2024","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2026.119045_bib55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.lfs.2016.01.020","article-title":"Moderate additive effects of endothelin receptor A blockade in Ren-2 transgenic rats subjected to various types of RAS blockade","volume":"159","author":"Van\u011b\u010dkov\u00e1","year":"2016","journal-title":"Life Sci."},{"issue":"21","key":"10.1016\/j.biopha.2026.119045_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112823","article-title":"Enhanced cardiorenal protective effects of combining SGLT2 inhibition, endothelin receptor antagonism and RAS blockade in type 2 diabetic mice","volume":"23","author":"Vergara","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2026.119045_bib57","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/ki.2011.451","article-title":"Synthesis and secretion of renin in mice with induced genetic mutations","volume":"81","author":"Schnermann","year":"2012","journal-title":"Kidney Int."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226000776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226000776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:42:33Z","timestamp":1781880153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226000776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":57,"alternative-id":["S0753332226000776"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119045","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin in combination with trandolapril but not with triple therapy improves glucose and lipid metabolism in non-diabetic hypertensive model","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119045"}}